PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China

Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) in China; however, the prognostic factors associated with effects in these patients are still controversial. In this study, we retrospectively reviewed the data fro...

Full description

Bibliographic Details
Main Authors: Kai-Jie Wu, Xin-Qi Pei, Ge Tian, Da-Peng Wu, Jin-Hai Fan, Yu-Mei Jiang, Da-Lin He
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Asian Journal of Andrology
Subjects:
castration-resistant prostate cancer; chemotherapy; docetaxel; prostate-specific antigen; survival; time to nadir
Online Access:http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=2;spage=173;epage=177;aulast=Wu

Internet

http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=2;spage=173;epage=177;aulast=Wu

Similar Items